VolitionRx Limited said its lateral flow finger-prick prototype for Nu.Q® NETs produced results highly correlated with the company's established automated Nu.Q® NETs assay in critically ill sepsis patients, with a Spearman correlation of 0.85 and a Pearson correlation of 0.881. The company said the format could help clinicians rapidly identify high-risk patients in the emergency room or at the bedside without relying on centralized laboratories, broadening access in countries with weaker lab infrastructure and expanding the addressable market for NETosis testing to $3.8 billion. Volition said the study, part of the SUMMIT program, compared capillary blood and plasma samples from intensive care patients and builds on earlier results showing correlation in whole venous blood and successful nucleosome detection in capillary blood. The company said it is targeting NGO partnerships and other collaborations in low income countries as it pursues commercialization against a global sepsis burden it cited at about 166 million cases, with sepsis-related deaths representing 31.5% of total global deaths in 2021.